CD274 and neoplasm: Specifically, targeting key immune checkpoints—cytotoxic T lymphocyte-associated antigen 4 and programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1)—releases inhibitory signals that constrain T cells’ activation, thereby eliciting robust and sustained anti-tumor immunity [2,3].